The following sources were cited in SAP Digital Futures Issue 16 Gene Editing: Big Science, Big Business
The gene- editing market is expected to reach US$3.5 billion by 2019 and has a range of applications.
Genome Editing/Genome Engineering Market by Application (Cell Line Engineering, Animal & Plant Genetic Engineering), Technology (CRISPR, Antisense, TALEN, Zinc Finger Nuclease), & End User (Biotechnology & Pharmaceutical, CRO) – Global Forecast to 2019, MarketsandMarkets, April 2015, http://www.marketsandmarkets.com/Market-Reports/genome-editing-engineering-market-231037000.html.
Gene editing may be used to treat chronic diseases and address human organ shortages.
Abdullah Ely, Buhle Moyo, and Patrick Arbuthnot, “Progress with Developing Use of Gene Editing to Cure Chronic Infection with Hepatitis B Virus,” Molecular Therapy, February 26, 2016, http://www.nature.com/mt/journal/v24/n4/full/mt201643a.html
Tanya Lewis, “7 Major Advancements in Gene Editing in 2015,” World Economic Forum, December 30, 2015, https://www.weforum.org/agenda/2015/12/7-major-advancements-in-gene-editing-in-2015/
Scientists are using CRISPR to create a population of mosquitoes resistant to malaria.
Tanja Lewis, “Scientists tweaked mosquito DNA to block malaria in its tracks,” Business Insider, November 23, 2015, http://www.businessinsider.com/mosquito-dna-tweaked-to-stop-malaria-via-gene-drive-2015-11
DuPont is growing edited corn and wheat plants to resist drought and improve yields.
Antonio Regalado, “DuPont Predicts CRISPR Plants on Dinner Plates in Five Years,” MIT Technology Review, October 8, 2016, https://www.technologyreview.com/s/542311/dupont-predicts-crispr-plants-on-dinner-plates-in-five-years/
Novartis is working with gene-editing startups on research tools for drug discovery.
“Novartis Collaborates with Intellia Therapeutics and Caribou Biosciences to Explore Making Medicines and Drug Discovery Tools with CRISPR Genome Editing Technology” [press release], Novartis, January 7, 2015, https://www.novartis.com/news/media-releases/novartis-collaborates-intellia-therapeutics-and-caribou-biosciences-explore